Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Preclinical studies of WVE-210...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)

Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)

Bibliographic Details
Main Authors: Panzara, M, Zhang, J, Rinaldi, C, McClorey, G, Bowman, K, Butler, D, Dodart, J, Frank-Kamenetsky, M, Iwamoto, N, Kothari, N, Lu, G, Mathieu, S, M, M, Melkonian, M, Menon, S, Standley, S, Yang, H, Zhong, Z, Wood, M, Vargeese, C
Format: Conference item
Published: Elsevier 2017
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD
    by: Yuanjing Liu, et al.
    Published: (2022-06-01)
  • Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models
    by: Yuanjing Liu, et al.
    Published: (2021-02-01)
  • Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
    by: Koo, T, et al.
    Published: (2013)
  • Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy
    by: Milyard Assefa, et al.
    Published: (2024-04-01)
  • A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
    by: Monika Hiller, et al.
    Published: (2018-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs